Ocular Hypertension, Primary Open-angle Glaucoma (POAG) Completed Phase Trials for Tafluprost (DB08819)

Also known as: Glaucoma Open-Angle Primary / Primary Open-Angle Glaucoma / Primary Open Angle Glaucoma (POAG) / Glaucoma, Primary Open Angle / Glaucoma Primary Open Angle / Glaucoma, Primary Open Angle (POAG) / Primary Glaucoma Open-Angle / Primary Open Angle Glaucoma / Primary Open-Angle Glaucoma (POAG) / Primary Glaucoma, Open Angle / Primary Open- Angle Glaucoma / Primary Open-Angle Glaucoma, Ocular Hypertension / Primary Open Angle Glaucoma, Ocular Hypertension / Open-angle glaucoma / Chronic simple glaucoma / Primary open angle glaucoma (disorder) / Open angle glaucoma NOS / Pigmentary glaucoma / Open angle glaucoma / Open-angle glaucoma NOS (disorder) / Open-angle glaucoma (disorder) / Glaucoma, Open-Angle / Unspecified open-angle glaucoma / Unspecified open-angle glaucoma (disorder) / Open-angle glaucoma, unspecified / Advanced open-angle glaucoma (disorder) / Glaucoma simplex / Pigmentary glaucoma (disorder)

IndicationStatusPhase
DBCOND0088544 (Ocular Hypertension, Primary Open-angle Glaucoma (POAG))CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04461249Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
NCT04737928Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)Treatment